Study of rhIL-15 with immunotherapy and chemo for neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs (rhIL-15, dinutuximab, irinotecan, and temozolomide) for children and young adults whose neuroblastoma has come back or hasn't responded to other treatments. The goal is to see if this mix can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 3 and 35 years old.
- Neuroblastoma must have come back or not gone away after at least one prior round of treatment.
- There must be signs of active cancer that can be seen on scans (MIBG, PET, MRI, or CT) or in a bone marrow sample.
- You must have recovered from the side effects of any recent cancer treatments.
- Your heart, lungs, kidneys, and blood counts must be working well enough (specific tests will be done).
- You cannot be pregnant or nursing, and must agree to use effective birth control during and for a few months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.